The FDA has approved the first dual-agent eye drop to treat presbyopia, a condition that causes gradual loss of near vision in adults.

Smartphone use now exceeds three hours a day on average, while total daily screen time for many adults crosses six hours.

Solar eclipses occur when the moon moves between the sun and the earth, and blocks the light of the sun from reaching earth.

Combining two eye drops that have been on the market for at least 30 years each has earned Tenpoint Therapeutics an FDA ...

Tenpoint Therapeutics’ Yuvezzi gets US FDA nod; the first and only combo eye drop approved to treat presbyopia: London Saturday, January 31, 2026, 14:00 Hrs [IST] Tenpoint Thera ...

The FDA approved Yuvezzi, an eye drop for the treatment of presbyopia, with broad U.S. availability expected in the second quarter, according to a press release from Tenpoint Therapeutics. Yuvezzi ...

Tenpoint Therapeutics’ Yuvezzi brings a combination approach to presbyopia compared to single mechanisms of action offered by once-daily eye drops from Orasis Pharmaceuticals, Lenz Therapeutics, and ...

YUVEZZI (TM) (carbachol and brimonidine tartrate ophthalmic solution) 2.75%/0.1% is a dual-agent eye drop approved by the U.S. Food & Drug Administration (FDA) for the treatment of presbyopia, a ...

Yuvezzi, a combination cholinergic agonist and alpha-adrenergic agonist, is now FDA-approved as a once-daily treatment for ...

In 20 years, we'll look back nostalgically on the Vision Pro from our Hyper Apple Vision X and talk about how, in spite of its flaws, more than any other device, it kickstarted the spatial computing ...

YUVEZZI (carbachol and brimonidine tartrate ophthalmic solution) 2.75%/0.1% is the only dual-agent presbyopia-correcting eye drop intentionally designed to deliver durability, tolerability, and safety ...

In this Forensic View, we continue our series on major cognitive elements of stress. In this post, we’ll examine one of the most important aspects of high-stress environments: tunnel vision. Tunnel ...